The Evolving Role of Stereotactic Body Radiation Therapy for Head and Neck Cancer: Where Do We Stand?

Stereotactic body radiation therapy (SBRT) is a precise and conformal radiation therapy (RT) that aims to deliver a high dose of radiation to the tumor whilst sparing surrounding normal tissue, making it an attractive option for head and neck cancer (HNC) patients who are not suitable for the tradit...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2023-10, Vol.15 (20), p.5010
Main Authors: Mohamad, Issa, Karam, Irene, El-Sehemy, Ahmed, Abu-Gheida, Ibrahim, Al-Ibraheem, Akram, AL-Assaf, Hossam, Aldehaim, Mohammed, Alghamdi, Majed, Alotain, Ibrahim, Ashour, May, Bushehri, Ahmad, ElHaddad, Mostafa, Hosni, Ali
Format: Article
Language:English
Subjects:
Brachytherapy
Cancer therapies
Care and treatment
Cell cycle
Fractionation
Head & neck cancer
Head and neck cancer
Hypoxia
Immunotherapy
Patients
Planning
Radiation therapy
Radiotherapy
Review
Toxicity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Stereotactic body radiation therapy (SBRT) is a precise and conformal radiation therapy (RT) that aims to deliver a high dose of radiation to the tumor whilst sparing surrounding normal tissue, making it an attractive option for head and neck cancer (HNC) patients who are not suitable for the traditional long course of RT with comprehensive RT target volume. Definitive SBRT for HNC has been investigated in different settings, including early stage glottis cancer, and as an alternative to brachytherapy boost after external beam RT. It is also used as a primary treatment option for elderly or medically unfit patients. More recently, an SBRT combination with immunotherapy in the neoadjuvant setting for HNC showed promising results. Salvage or adjuvant SBRT for HNC can be used in appropriately selected cases. Future studies are warranted to determine the optimum dose and fractionation schedules in any of these indications.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers15205010